Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.

导出 OA

翻译打印收藏纠错

作者： Jesús,Troya ^[1] ; Paul,Bastard ^[2] ; Laura,Planas-Serra ^[3] ; Pablo,Ryan ^[4] ; Montse,Ruiz ^[5] ; María,de Carranza ^[6] ; Juan,Torres ^[5] ; Amalia,Martínez ^[6] ; Laurent,Abel ^[6] ; Jean-Laurent,Casanova ^[7] ; Aurora,Pujol ^[2]

作者单位： Department of Internal Medicine, Infanta Leonor University Hospital, Madrid, Spain. jestrogar@hotmail.com. ^[1] Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France. ^[2] Imagine Institute, University of Paris, Paris, France. ^[3] St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY, USA. ^[4] Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. ^[5] Department of Internal Medicine, Infanta Leonor University Hospital, Madrid, Spain. ^[6] Intensive Care Unit, Infanta Leonor University Hospital, Madrid, Spain. ^[7] Howard Hughes Medical Institute, New York, NY, USA. ^[8] Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain. ^[9] Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Catalonia, Spain. ^[10]

关键词 COVID-19 severity biomarkers subcutaneous interferon-beta 1b type I IFN neutralizing autoantibodies